New hope for hard-to-treat colorectal cancer: triple-drug combo enters human trials
Disease control
Recruiting now
This study is testing a new drug called ABT-301 combined with two other drugs (tislelizumab and bevacizumab) in people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if the combination is safe and can shrink tumors. Abo…
Phase: PHASE1, PHASE2 • Sponsor: Anbogen Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC